Celcuity (CELC)

• Market cap: $344M
• 1 day: -8.41%
• 5 days: -12.14%
• 1 month: 4.04%
• 3 months: -29.47%
• 6 months: -36.49%
• Year to date: -29.47%
• 1 year: -55.44%
• 5 years: 67.75%
• 10 years: -35.20%
• Sector: Healthcare
• Industry: Medical Laboratories

About: Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Employees: 55

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

22,800% more call options, than puts

Call options by funds: $229K | Put options by funds: $1K

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

23% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 30

0.72% more ownership

Funds ownership: 81.11% [Q3] → 81.83% (+0.72%) [Q4]

10% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 21

2% less funds holding

Funds holding: 105 [Q3] → 103 (-2) [Q4]

11% less capital invested

Capital invested by funds: $450M [Q3] → $402M (-$47.8M) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $27 192% upside
• Avg. target: $28 202% upside
• High target: $29 213% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Swayampakula Ramakanth 22% 1-year accuracy 45 / 203 met price target	192% upside $27	Buy Reiterated	1 Apr 2025
Needham Gil Blum 7% 1-year accuracy 12 / 162 met price target	213% upside $29	Buy Reiterated	1 Apr 2025